PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Cabozantinib for the treatment of kidney cancer.

Abstract Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. Areas covered: In the METEOR trial, cabozantinib demonstrated significantly improved efficacy in all three endpoints; response rates, progression free survival and overall survival in a randomized trial with everolimus as an active comparator. Cabozantinib also showed activity in the front line setting in RCC within the CABOSUN trial. The study randomized untreated metastatic RCC patients to either cabozantinib or sunitinib and the former showed improved progression free survival which was the primary endpoint. The future holds promise for indications in other malignancies, given the preliminary efficacy and unique mechanism of action of cabozantinib. In this review we address the mechanism of action, pharmacodynamics and pharmacokinetics of cabozantinib, and also review the development pathway of this agent in the treatment of advanced renal cell carcinoma. The potential benefit in specific patient populations, such as poor risk patients and bone metastases subgroups is also discussed. Expert commentary: The clinical applications of cabozantinib will be addressed within the context of the current competitive therapeutic landscape of RCC.
PMID
Related Publications

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Cabozantinib Approved for Renal Cell Carcinoma.

Cabozantinib: A Review in Advanced Renal Cell Carcinoma.

Cabozantinib for the treatment of renal cell carcinoma.

Authors

Mayor MeshTerms
Keywords

CABOSUN

Cabozantinib

MET

METEOR

RCC

renal cell carcinoma

targeted therapy

Journal Title expert review of anticancer therapy
Publication Year Start




PMID- 28633552
OWN - NLM
STAT- MEDLINE
DA  - 20170621
DCOM- 20170707
LR  - 20170707
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 17
IP  - 7
DP  - 2017 Jul
TI  - Cabozantinib for the treatment of kidney cancer.
PG  - 577-584
LID - 10.1080/14737140.2017.1344553 [doi]
AB  - INTRODUCTION: Cabozantinib is a small molecule tyrosine kinase inhibitor that
      initially showed activity in medullary thyroid cancer and was recently approved
      by the Food and Drug Administration for the treatment of metastatic renal cell
      carcinoma after progression on first line therapy. Areas covered: In the METEOR
      trial, cabozantinib demonstrated significantly improved efficacy in all three
      endpoints; response rates, progression free survival and overall survival in a
      randomized trial with everolimus as an active comparator. Cabozantinib also
      showed activity in the front line setting in RCC within the CABOSUN trial. The
      study randomized untreated metastatic RCC patients to either cabozantinib or
      sunitinib and the former showed improved progression free survival which was the 
      primary endpoint. The future holds promise for indications in other malignancies,
      given the preliminary efficacy and unique mechanism of action of cabozantinib. In
      this review we address the mechanism of action, pharmacodynamics and
      pharmacokinetics of cabozantinib, and also review the development pathway of this
      agent in the treatment of advanced renal cell carcinoma. The potential benefit in
      specific patient populations, such as poor risk patients and bone metastases
      subgroups is also discussed. Expert commentary: The clinical applications of
      cabozantinib will be addressed within the context of the current competitive
      therapeutic landscape of RCC.
FAU - Abdelaziz, Ahmed
AU  - Abdelaziz A
AD  - a Department of Oncology , Wayne State University/Barbara Ann Karmanos Cancer
      Institute , Detroit , MI , USA.
FAU - Vaishampayan, Ulka
AU  - Vaishampayan U
AD  - a Department of Oncology , Wayne State University/Barbara Ann Karmanos Cancer
      Institute , Detroit , MI , USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Anilides)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 1C39JW444G (cabozantinib)
SB  - IM
MH  - Anilides/pharmacokinetics/pharmacology/*therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/pharmacokinetics/pharmacology/therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Neoplasm Metastasis
MH  - Protein Kinase Inhibitors/pharmacokinetics/pharmacology/therapeutic use
MH  - Pyridines/pharmacokinetics/pharmacology/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Survival Rate
OTO - NOTNLM
OT  - CABOSUN
OT  - Cabozantinib
OT  - MET
OT  - METEOR
OT  - RCC
OT  - renal cell carcinoma
OT  - targeted therapy
EDAT- 2017/06/22 06:00
MHDA- 2017/07/08 06:00
CRDT- 2017/06/22 06:00
AID - 10.1080/14737140.2017.1344553 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2017 Jul;17(7):577-584. doi:
      10.1080/14737140.2017.1344553.